DBV Technologies Files 2026 Half-Year Report: Progress on VIASKIN Food Allergy Treatment
DBV Technologies, a clinical-stage biopharmaceutical company focused on the treatment of food allergies, has officially filed its 2026 half-year financial report with the Autorité des Marchés Financiers (AMF), France’s financial markets regulator. This regulatory disclosure, published in accordance with transparency requirements for publicly traded companies, provides an updated look at the company’s operational progress and … Read more